Perrigo Announces Tentative FDA Approval For The Generic Version Of Prolensa(R) Ophthalmic Solution 0.07%

DUBLIN, Jan. 3, 2018 -- (Healthcare Sales & Marketing Network) -- Perrigo Company plc (NYSE; TASE: PRGO) today announced it has received tentative approval from the U.S. Food and Drug Administration for the generic version of Prolensa® (bromfenac opht... Biopharmaceuticals, Generics, Ophthalmology, FDA Perrigo, bromfenac, Prolensa, cataract surgery

http://salesandmarketingnetwork.com/news_release_bs.html?ID=2043347

Source: HSMN NewsFeed - January 3, 2018 Category: Pharmaceuticals Source Type: news

More News: Cataract Removal | Cataracts | Food and Drug Administration (FDA) | Marketing | Opthalmology